Nycomed Says Growth in China Helped Revenues

Nycomed, a privately owned Swiss biopharma, said its recent acquisition of Guangdong Techpool Biopharma and a direct sales model in China boosted the company’s revenues in Q2. Asia-Pacific, Africa and Middle East saw revenues climb by 81%, though the company did not break out China sales separately. In November 2010, Nycomed announced it would spend $210 million to purchase a 51% stake in Techpool, a biologics company. More details.... Share this with colleagues:   var switchTo5x=true; stLight.options({publisher:'d7871f5b-67bc-4d30-b66f-1465d0b97213'});